Abstract:Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal and morbid malignancies today. Although newer chemotherapy regimens such as FOLFIRINOX and gemcitabine/nab-paclitaxel have made modest improvements in patient survival, more effective therapies are needed. With the exception of the EGFR inhibitor erlotinib, there are no approved, targeted therapies for metastatic PDA. Recent work demonstrated the importance of PIM kinases, particularly PIM1 and PIM3, in PDA. PIM kinases are involved in apoptosis,… Show more
“…Pre‐clinical studies in CLL (Chen et al , 2009c; Decker et al , ; Cervantes‐Gomez et al , ), other haematological malignancies (Garcia et al , ; Keane et al , ; Brunen et al , ; Nair et al , ; Paino et al , ) and solid tumours (Chen et al , 2009b, ; Foulks et al , ; Braso‐Maristany et al , ; O'Hayer et al , ; Warfel et al , ), suggest that, owing to their important roles in tumour cell biology, the PIM family of kinases may represent targets for novel, single agent or combination therapies. This concept is illustrated by a recent study in which the combination of a PIM and a PI3 kinase inhibitor, NMS‐P645 and GDC‐0941 respectively, had significantly more anti‐proliferative activity than either inhibitor alone against pancreatic cancer cells (Mologni et al , ).…”
Section: Discussionmentioning
confidence: 99%
“…The PIM kinases are a family of serine/threonine kinases with documented roles in drug‐resistance (Chen et al , 2009a), apoptosis (Braso‐Maristany et al , ), cell cycle (Chen et al , ) and DNA damage repair (Chen et al , ). In pancreatic ductal carcinoma (PDA) an increase in PIM1 expression induced during hypoxic stress was concomitant with resistance to oxaliplatin (O'Hayer et al , ), while induction of PIM2 expression in an in vitro stromal co‐culture model of multiple myeloma was associated with resistance to the proteasome inhibitor bortezomib (Reidy et al , ). Pre‐clinical studies suggest that further investigation of PIM kinase inhibitors may also be warranted in CLL (Chen et al , 2009c; Decker et al , ; Garcia et al , ), although no studies to date have examined the effects of inhibitors of either the PIM or PI3 kinases on CLL cells under reduced oxygen tensions.…”
mentioning
confidence: 99%
“…Studies in multiple myeloma (Reidy et al , ) and PDA (O'Hayer et al , ) demonstrate the potential of IBL‐202, an inhibitor of both the PIM and PI3 kinases, for the treatment of a variety of tumour types under conditions that mimic the tumour microenvironment and confer resistance to more conventional therapies. In the current study, we explored the effects of IBL‐202 under in vitro conditions that mimic the hypoxic CLL tumour microenvironment (Herishanu et al , ).…”
Despite significant advances in treatment, chronic lymphocytic leukaemia (CLL) remains an incurable disease. Ibrutinib and idelalisib, which inhibit Bruton Tyrosine kinase (BTK) and phosphoinositol-3 (PI3) kinase-δ respectively, have become important treatment options for the disease and demonstrate the potential of targeting components of the B-cell receptor-signalling pathway. IBL-202 is a dual inhibitor of the PIM and PI3 kinases. Synergy between the pan-PIM inhibitor, pPIMi, and idelalisib against a range of haematological cell lines and primary CLL cells supports the rationale for preclinical studies of IBL-202 in CLL. Importantly, IBL-202, but not idelalisib, was cytotoxic against CLL cells under in vitro conditions that mimic the hypoxic tumour microenvironment. The significant effects of IBL-202 on CD49d and CXCR4 expression and migration, cycle and proliferation of CLL cells suggest the drug may also interfere with the migratory and proliferative capacity of the leukaemic cells. Collectively, these data demonstrate that dual inhibition of the PIM and PI3 kinases by IBL-202 may be an effective strategy for targeting CLL cells, particularly within the environmental niches known to confer drug-resistance.
“…Pre‐clinical studies in CLL (Chen et al , 2009c; Decker et al , ; Cervantes‐Gomez et al , ), other haematological malignancies (Garcia et al , ; Keane et al , ; Brunen et al , ; Nair et al , ; Paino et al , ) and solid tumours (Chen et al , 2009b, ; Foulks et al , ; Braso‐Maristany et al , ; O'Hayer et al , ; Warfel et al , ), suggest that, owing to their important roles in tumour cell biology, the PIM family of kinases may represent targets for novel, single agent or combination therapies. This concept is illustrated by a recent study in which the combination of a PIM and a PI3 kinase inhibitor, NMS‐P645 and GDC‐0941 respectively, had significantly more anti‐proliferative activity than either inhibitor alone against pancreatic cancer cells (Mologni et al , ).…”
Section: Discussionmentioning
confidence: 99%
“…The PIM kinases are a family of serine/threonine kinases with documented roles in drug‐resistance (Chen et al , 2009a), apoptosis (Braso‐Maristany et al , ), cell cycle (Chen et al , ) and DNA damage repair (Chen et al , ). In pancreatic ductal carcinoma (PDA) an increase in PIM1 expression induced during hypoxic stress was concomitant with resistance to oxaliplatin (O'Hayer et al , ), while induction of PIM2 expression in an in vitro stromal co‐culture model of multiple myeloma was associated with resistance to the proteasome inhibitor bortezomib (Reidy et al , ). Pre‐clinical studies suggest that further investigation of PIM kinase inhibitors may also be warranted in CLL (Chen et al , 2009c; Decker et al , ; Garcia et al , ), although no studies to date have examined the effects of inhibitors of either the PIM or PI3 kinases on CLL cells under reduced oxygen tensions.…”
mentioning
confidence: 99%
“…Studies in multiple myeloma (Reidy et al , ) and PDA (O'Hayer et al , ) demonstrate the potential of IBL‐202, an inhibitor of both the PIM and PI3 kinases, for the treatment of a variety of tumour types under conditions that mimic the tumour microenvironment and confer resistance to more conventional therapies. In the current study, we explored the effects of IBL‐202 under in vitro conditions that mimic the hypoxic CLL tumour microenvironment (Herishanu et al , ).…”
Despite significant advances in treatment, chronic lymphocytic leukaemia (CLL) remains an incurable disease. Ibrutinib and idelalisib, which inhibit Bruton Tyrosine kinase (BTK) and phosphoinositol-3 (PI3) kinase-δ respectively, have become important treatment options for the disease and demonstrate the potential of targeting components of the B-cell receptor-signalling pathway. IBL-202 is a dual inhibitor of the PIM and PI3 kinases. Synergy between the pan-PIM inhibitor, pPIMi, and idelalisib against a range of haematological cell lines and primary CLL cells supports the rationale for preclinical studies of IBL-202 in CLL. Importantly, IBL-202, but not idelalisib, was cytotoxic against CLL cells under in vitro conditions that mimic the hypoxic tumour microenvironment. The significant effects of IBL-202 on CD49d and CXCR4 expression and migration, cycle and proliferation of CLL cells suggest the drug may also interfere with the migratory and proliferative capacity of the leukaemic cells. Collectively, these data demonstrate that dual inhibition of the PIM and PI3 kinases by IBL-202 may be an effective strategy for targeting CLL cells, particularly within the environmental niches known to confer drug-resistance.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.